H. Lundbeck A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLBBF research report →
Price Chart
About the company
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, and other worldwide regions.
- CEO
- Charl van Zyl
- IPO
- 2022
- Employees
- 5,214
- HQ
- Valby, CR, DK
Get TickerSpark's AI analysis on HLBBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.27B
- P/E
- 10.40
- Fwd P/E
- 1.39
- PEG
- 0.91
- P/S
- 1.26
- P/B
- 1.50
- EV/EBITDA
- 4.78
- Div Yield
- 2.83%
- Gross Margin
- 78.27%
- Op Margin
- 27.21%
- Net Margin
- 15.13%
- ROE
- 15.13%
- ROIC
- 11.62%
Latest fiscal year · YoY change
- Revenue
- $24.30B+10.4%
- Gross Profit
- $19.33B+8.8%
- Op Income
- $6.33B
- Net Income
- $3.18B+1.3%
- EPS
- $3.21+1.3%
- OCF Growth
- +46.9%
- FCF Growth
- +57.0%
- 52W High
- $7.55
- 52W Low
- $5.51
- 50D MA
- $6.64
- 200D MA
- $6.60
- Beta
- 0.26
- RSI (14)
- 54
- Avg Volume
- 66
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the HLBBF Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 38.5%
- Shares Outstanding
- 793.13M
- Float Shares
- 305.02M
Our HLBBF coverage
Recent articles, reports, and earnings notes.
No research on HLBBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLBBF report →H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 19
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
seekingalpha.com · Jun 5
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
seekingalpha.com · Mar 18
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 4
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
wsj.com · Nov 14
H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 12
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
prnewswire.com · Mar 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.